Smoking, Most DMTs Not Associated With Severe COVID-19 in Patients With MS
December 11, 2021 by Skylar Jeremias Although obesity, diabetes, and certain comorbidities were all detected as risk factors…
An interpretable machine learning model to explain the interplay between brain lesions and cortical atrophy in multiple sclerosis
============================ By DocWire News – Featured Reading – December 11, 2021 Annu Int Conf IEEE Eng Med Biol Soc. 2021…
Stuart Schlossman
Study examines the roles of microglia and monocytes in myelin destruction in patients with early multiple sclerosis
Multiple Sclerosis: Microglia, Monocytes, and Macrophage-Mediated Demyelination John W Prineas 1, John D E Parratt 2 PMID: 34553215 PMCID: PMC8557350 DOI: 10.1093/jnen/nlab083 Abstract This…
Stuart Schlossman
Stem Cell Transplant Induces Multiple Sclerosis Remission
At a Glance Immunosuppressive therapy followed by stem cell transplantation induced remission of a common form of multiple sclerosis…
Stuart Schlossman
A cellular map of brain lesions in multiple sclerosis
At a Glance Researchers created a detailed map of cells in the expanding lesions involved in more disabling forms…
Stuart Schlossman
Relapse comparable among common DMTs for MS
Dimethyl fumarate and fingolimod appeared to have no significant difference in relapse rates, and rituximab appeared to have better relapse…
Stuart Schlossman
Teriflunomide Study in Kids with MS Does Not Meet Primary Endpoint, But Reduces MRI Activity
November 29, 2021 —Do We Need Different Ways to Measure Treatment Effectiveness in Children with MS?In a recently published study…
Stuart Schlossman
Siponimod’s Efficacy on Secondary Progressive MS in Older age groups
October 28, 2021 – Le Hua, MD ranscript below. Le Hua, MD: The original EXPAND study had been presented, so…
Stuart Schlossman
Never Drinking Alcohol Tied to ‘Significantly’ Higher MS Risk
by Marisa Wexler MS | November 2, 2021 Not drinking alcohol significantly increases the risk of developing multiple sclerosis (MS), especially if a person is…
Stuart Schlossman
T20K Combo Shows Promise in MS Preclinical Studies
New preclinical data continues to support the potential of Cyxone’s investigational plant-derived peptide T20K for the treatment of multiple sclerosis (MS). In a collaboration with…
Stuart Schlossman
